AAV2-kdrVMAT2

AAV2-kdrVMAT2 is an experimental gene therapy product based on an adeno-associated virus serotype 2 (AAV2) vector engineered to deliver and express a modified form of the vesicular monoamine transporter 2 (VMAT2) gene, often referred to as "kdrVMAT2" (kinase-dead resistant VMAT2). The construct is designed primarily for central nervous system disorders where dopamine signaling is compromised, such as Parkinson's disease. The rationale is that enhancing or restoring VMAT2 function may improve dopamine packaging, release, and synaptic function in affected brain regions. AAV2 vectors are widely used in CNS gene therapy for their tropism and ability to transduce neurons with high efficiency and relatively low immunogenicity. The kdrVMAT2 variant is often engineered to be resistant to particular regulatory pathways to ensure robust transgene expression. Detailed human data for AAV2-kdrVMAT2 as an investigational product are not available in the indexed clinical trial or published literature databases as of October 2025, indicating it is an early-stage experimental therapy possibly in preclinical development.